StockWatch
·

Modi Naturals Limited Q2 FY27 Results

MODINATURQ2 FY27 Results
Filing
Result:Steady· Market: Crashed#Margin squeeze
MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue204.9031.7%39.4%
Total Income205.2632.2%39.0%
Expenditure191.9437.8%41.3%
PBT13.3216.5%12.1%
Net Profit11.0211.8%9.4%
OPM9.09%5.16pp1.35pp
NPM5.37%2.68pp1.45pp
EPS8.3311.8%9.9%
View full financials

Revenue grew a strong 39.4% YoY but OPM/NPM compressed (9.09% vs 10.44%, 5.37% vs 6.82%), leaving adjusted PAT growth at just 9.4% — in-line quality with margin squeeze offsetting top-line strength.

Q2 FY-2027 RESULTS · MODINATUR

Modi Naturals Q2 FY27: PAT up just 9% YoY as branded/bulk margins offset ethanol surge

PAT +9.45% YoY · revenue +39.4% · margins compressing

06 Nov 2026 · 3 min read
Revenue

₹204.9 Cr

+39.4% YoY

PAT (consolidated)

₹11.02 Cr

+9.45% YoY

Net margin

5.37%

-1.5pp YoY

EPS

₹8.33

Consolidated revenue rose to ₹204.90 Cr, up 39.4% YoY and 31.7% QoQ, almost entirely on the Ethanol segment (₹117.46 Cr, +37.9% YoY, +54.1% QoQ) as the doubled ethanol capacity continues to ramp. But consolidated PAT of ₹11.02 Cr grew only 9.4% YoY and fell 11.8% QoQ from ₹12.50 Cr in Q1 FY27 (EPS ₹8.33 vs ₹7.58 YoY and ₹9.44 QoQ), so profit growth trailed topline growth by a wide margin. NPM compressed to 5.37% from 6.82% (YoY) and 8.05% (QoQ); OPM fell to 9.26% from 10.44% (YoY) and 14.25% (QoQ).

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹204.9 Cr+31.7%+39.4%
Expenses₹191.94 Cr+37.8%+41.3%
PAT₹11.02 Cr-11.82%+9.45%
Net margin5.37%-2.7pp-1.5pp
EPS₹8.33-11.8%+9.9%

The margin squeeze did not come from Ethanol, which held EBITDA margin at 15.78% this quarter (18.15% for H1) — at or above management's own 12-15% long-term guide for the division. It came from the other two segments: Branded EBITDA margin collapsed to 2.12% (from 9.38% in Q1 and 7.16% a year ago), and Bulk swung to a segment EBITDA loss of ₹0.51 Cr (from +₹1.25 Cr in Q1, +₹0.40 Cr a year ago). The standalone entity, which carries only Branded and Bulk (Ethanol sits entirely in Modi Biotech, consolidated-only), was effectively breakeven at ₹0.02 Cr PAT on ₹0.01 Cr PBT, against ₹2.63 Cr a year ago — a stark reminder that the core consumer oils/food business is under real pressure even as ethanol drives the consolidated headline. No press release accompanied this filing, so this reading is drawn from the result statement and the prior concall only.

₹
273.67310.7347.73384.75421.78321.7508-0308-2609-1810-1311-0511-06Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹321.75, up 6.9% over the past month of trading.

₹ Cr
07.3414.6922.0310.49Q1 FY26rev ₹155 Cr10.07Q2 FY26rev ₹147 Cr10.04Q3 FY26rev ₹174 Cr19.67Q4 FY26rev ₹243 Cr12.5Q1 FY27rev ₹156 Cr11.02Q2 FY27rev ₹205 Cr
Quarterly consolidated PAT, ₹ Crore
What management guided (4 FY-2026 call)
Management provides a conservative FY27 revenue guidance of INR 950 crores, confidently expecting to exceed it as they ramp up their newly doubled ethanol capacity, which could support over INR 1,100 crores in revenue at full utilization. The long-term sustainable EBITDA margin for the ethanol division is pegged at 12-

— This quarter: met

Against management's FY27 guidance (revenue ₹925-965 Cr, EBITDA ₹100-105 Cr, PAT ₹66-70 Cr, confirmed post the May 2026 concall), H1 FY27 consolidated revenue of ₹361.95 Cr is ~38% of the full-year range and PAT of ₹23.53 Cr is ~35% — close to the company's own historical H1 skew (H1 FY26 was 42% of FY26 revenue and 41% of FY26 PAT), so the pace looks broadly on track rather than off course, though H2 will need the margin trend to stabilise rather than repeat this quarter's compression. No analyst consensus estimates for this specific quarter turned up in search (small-cap, thin broker coverage), so street comparison is unknown. The only hard corporate development on record this quarter is the ₹140 Cr ethanol order win for Modi Biotech (17-Aug-2026), consistent with the ethanol-led revenue surge; management's May-2026 bullish, confident tone on ethanol is so far borne out, but its branded-division ambitions (medium-term ₹500 Cr target, H1 branded revenue ₹87.44 Cr) show no comparable momentum this quarter.

  • W1

    Branded segment EBITDA margin recovery from 2.12% this quarter back toward the 7-9% seen in Q1 FY27/Q2 FY26

  • W2

    Ethanol segment EBITDA margin sustaining near/above the 12-15% guided range as capacity utilisation scales further toward management's cited ₹1,100 Cr revenue potential

  • W3

    H2 FY27 pace vs full-year guidance of ₹925-965 Cr revenue and ₹66-70 Cr PAT, given H1 is at only ~38%/~35% of that range

Converted from ₹ Lakhs; limited-review unaudited results, no exceptional items this quarter or comparatives. Standalone entity excludes the Ethanol segment (held entirely via wholly-owned subsidiary Modi Biotech Pvt Ltd), which explains its near-breakeven PAT (₹0.02 Cr) vs ₹11.02 Cr consolidated.

Informational and educational content only. Not investment advice.